Tolerability of spironolactone as adjunctive treatment for heart failure in patients over 75 years of age [4]

Age and Ageing

Volumn 34, Issue 4, 2005, Pages 395-398

  Dinsdale, Claire ^a,c   Wani, Mushtaq ^a   Steward, John ^b   O'Mahony, M Sinead ^c  

^a MORRISTON HOSPITAL   (United Kingdom)

^b Welsh Cancer Intelligence and Surveillance Unit   (United Kingdom)

^c LLANDOUGH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; CREATININE; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FOSINOPRIL; LISINOPRIL; LOOP DIURETIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PERINDOPRIL; POTASSIUM; POTASSIUM SPARING DIURETIC AGENT; RAMIPRIL; SPIRONOLACTONE; DIURETIC AGENT;

AGED; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG FATALITY; DRUG MONITORING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GENERAL HOSPITAL; GERIATRIC CARE; HEART FAILURE; HUMAN; HYPERKALEMIA; HYPOTENSION; INCIDENCE; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LETTER; MAJOR CLINICAL STUDY; MALE; ORTHOSTATIC HYPOTENSION; POTASSIUM BLOOD LEVEL; PRACTICE GUIDELINE; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; AGE; ARTICLE; CHEMICALLY INDUCED DISORDER; CONGESTIVE HEART FAILURE;

DIGITALIS;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIURETICS; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; HYPERKALEMIA; KIDNEY FAILURE; MALE; RETROSPECTIVE STUDIES; SPIRONOLACTONE;

EID: 26944459667     PISSN: 00020729     EISSN: 14682834     Source Type: Journal    
DOI: 10.1093/ageing/afi104     Document Type: Letter

References (14)

1. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomised Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-17.
2. The RALES Investigators. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive cardiac failure (the Randomised Aldactone Evaluation Study). Am J Cardiol 1996; 78: 902-7.
3. Department of Health. NICE guidelines for treatment of heart failure. August 2003.
4. Berry C, McMurray JJ. Serious adverse events experienced by patients with chronic heart failure taking spironolactone. Heart 2001; 85: E8.
5. Berry C, McMurray JJ. Life-threatening hyperkalaemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone. Am J Med 2001; 111: 587.
6. Schepkens H, Vanholder R, Billiouw JM, Lamiere N. Life-threatening hyperkalaemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone; an analysis of 25 cases. Am J Med 2001; 110: 438-41.
7. Wrenger E, Muller R, Moesenthin M, Welte T, Frolich J, Neumann KH. Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers; analysis of 44 cases. BMJ 2003; 327: 147-9.
8. Juurlink DN, Mamdani MM, Lee DS et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004; 351: 543-51.
9. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
10. Bozkurt B, Agoston I, Knowlton AA. Complications of inappropriate use of spironolactone; when an old medicine spirals out of new guidelines. J Am Coll Cardiol 2003; 41; 211-4.
11. Svensson M, Gustafsson F, Galatius S, Hildebrandt PR, Atar D. Hyperkalaemia and impaired renal function in patients taking spironolactone for congestive heart failure; retrospective study. BMJ 2003; 327; 1141-2.
12. Cruz CS, Cruz AA, de Souza CAM. Hyperkalemia in congestive heart failure patients using ACE inhibitors and spironolactone. Nephrol Dial Transplant 2003; 18: 1814-19.
13. McMurray JJ, Matthews C. Consequences of fluid loss in patients with severe congestive cardiac failure taking ACE inhibitors. Postgrad Med J 1987; 63: 385.
14. Pitt B, Remme WJ, Zannad F et al. Eplerenone, a selective aldosterone blocker in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-21.